MSC-exosomes pretreated by Danshensu extracts pretreating to target the hsa-miR-27a-5p and STAT3-SHANK2 to enhanced antifibrotic therapy
This study highlighted the innovative use of Danshensu in enhancing MSC-derived exosome therapy for PF. The identification of the hsa-miR-27a-5p_R-1-STAT3-SHANK2 axis may reveal new molecular mechanisms underlying fibrosis, further research is needed to fully elucidate its impact on PF. The integration of Danshensu from traditional Chinese medicine into modern MSC exosome therapy represents a promising frontier in the development of novel treatments for fibrotic diseases.
Authors
- Jian Zhao (ORCID: https://orcid.org/0000-0002-4416-7334)
- Yukuan Tang (ORCID: https://orcid.org/0000-0003-3375-8283)
- Jing Liao (ORCID: https://orcid.org/0000-0001-5547-1342)
- Hanwei Chen (ORCID: https://orcid.org/0000-0002-9618-542X)
- Jianhao Li (ORCID: https://orcid.org/0000-0003-4893-1317)
- Lin Yang (ORCID: https://orcid.org/0000-0002-4028-9801)
- Weizhao Zhuang
- Jiabin Liang (ORCID: https://orcid.org/0000-0002-1047-9786)
- Qian Wang (ORCID: https://orcid.org/0009-0008-5363-8733)
- Chen Huang (ORCID: https://orcid.org/0000-0002-5707-7063)
- Fanghong Li
- Jinxian He
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Panyu Hospital of Chinese Medicine (CN)
- Panyu District Central Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Stem Cell Research & Therapy
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1186/s13287-025-04181-0
- Citations
- 7
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 5.64
Funders
- Guangzhou Medical University